Meeting
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
Authors
Jasmine Huynh
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Jasmine Huynh , May Thet Cho , Edward Jae-Hoon Kim , Min Ren , Carol Robbins , Carlos Amaya-Chanaga , Arndt Vogel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01761266
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 298)
DOI
10.1200/JCO.2021.39.3_suppl.298
Abstract #
298
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2020 Gastrointestinal Cancers Symposium
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
First Author: Angel Alsina
Poster
2020 Gastrointestinal Cancers Symposium
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).
First Author: Arndt Vogel
Poster
2022 ASCO Gastrointestinal Cancers Symposium
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.
First Author: Han Chong Toh